Skip to main content

Peer Review reports

From: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

Original Submission
21 Mar 2019 Submitted Original manuscript
3 Oct 2018 Reviewed Reviewer Report - Reviewer 2
Resubmission - Version 2
Submitted Manuscript version 2
Publishing
28 Mar 2019 Editorially accepted
14 Jun 2019 Article published 10.1186/s12885-019-5541-4

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us